Etheros Pharmaceuticals Corp.

NASHVILLE, TN · Founded 2022 · CIK 0002005132 · Biotech · Private

Neuroprotective small-molecule therapeutic compound extending lifespan in preclinical models

etherospharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$1.7M
3 Form D · Jun 2025
16 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raised· 1 of 2 same dayForm D · SEC$300,000
Private capital raised· 2 of 2 same dayForm D · SEC$775,000
Private capital raisedForm D · SEC$600,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2351WindMIL Therapeutics—$45M
2352Illuminare Biotechnologies Inc—$6.0M
2353Ostentus Therapeutics, Inc.—$1.8M
2354Etheros Pharmaceuticals Corp.—$1.7M
2355DeepCyte Inc.—$1.4M
2356Unnatural Products Inc.—$23M
2357CELLULAR LOGISTICS, INC.—$1.0M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Subhasish ChakrabortyExecutive Officer
  • Laura DuganDirector
  • Marc FeldmannDirector
  • Francis KnuettelDirector
  • Francis Knuettel IIDirector
  • John ScannellDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.